Literature DB >> 11571932

Disorders of prolactin secretion.

M E Molitch1.   

Abstract

Prolactinomas are a common cause of reproductive/sexual dysfunction. Once other causes of hyperprolactinemia have been excluded with a careful history and physical examination, routine chemistries, and an assay for TSH, MR imaging, or CT will delineate the size and extent of the tumor. Medical therapy is the initial treatment of choice. When infertility is the primary indication for treatment, bromocriptine use has an extensive safety record and is preferred. For other indications, cabergoline seems to be more efficacious and better tolerated. Transsphenoidal surgery remains an option, especially for patients with microadenomas, when medical therapy is ineffective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571932     DOI: 10.1016/s0889-8529(05)70203-6

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  17 in total

Review 1.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.

Authors:  L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

Review 3.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

4.  The pituitary stalk effect: is it a passing phenomenon?

Authors:  Marvin Bergsneider; Leili Mirsadraei; William H Yong; Noriko Salamon; Michael Linetsky; Marilene B Wang; David L McArthur; Anthony P Heaney
Journal:  J Neurooncol       Date:  2014-02-19       Impact factor: 4.130

5.  Metastatic renal cell carcinoma to the pituitary presenting with hyperprolactinemia.

Authors:  S Basaria; W H Westra; H Brem; R Salvatori
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

6.  Primary hypothyroidism in a child simulating a prolactin-secreting adenoma.

Authors:  Crésio Alves; Ana Cláudia Alves
Journal:  Childs Nerv Syst       Date:  2008-08-09       Impact factor: 1.475

Review 7.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 8.  Prolactin, psychological stress and environment in humans: adaptation and maladaptation.

Authors:  Luis Gonçalves Sobrinho
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

9.  The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas.

Authors:  Fangfang Zhang; Yinxing Huang; Chenyu Ding; Guoliang Huang; Shousen Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 10.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.